A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19.

Authors	Dave Singh, Maxim Bogus, Valentyn Moskalenko, Robert Lord, Edmund J Moran, Glenn D Crater, David L Bourdet, Nathan D Pfeifer, Jacky Woo, Elad Kaufman, David A Lombardi, Emily Y Weng, Tuan Nguyen, Ashley Woodcock, Brett Haumann, Rajeev Saggar
Journal	The European respiratory journal (Eur Respir J) Vol. 58 Issue 4 (10 2021) ISSN: 1399-3003 [Electronic] England
PMID	34210790 (Publication Type: Clinical Trial, Phase II, Letter)
Chemical References	Janus Kinase Inhibitors Janus Kinases
Topics	Administration, Inhalation COVID-19 Humans Janus Kinase Inhibitors Janus Kinases SARS-CoV-2

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!